Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine subcutaneous - Britannia Pharmaceuticals

Next Previous
X
Search
Drug Profile

Apomorphine subcutaneous - Britannia Pharmaceuticals

Alternative Names: APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; MOVAPO®; SPN-830

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Kyowa Kirin; STADA Arzneimittel; Supernus Pharmaceuticals; US WorldMeds
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 06 Aug 2024 Supernus Pharmaceuticals resubmitts New Drug Application for apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations in Parkinson’s disease
  • 08 May 2024 Supernus Pharmaceuticals intends to resubmit the NDA following further discussions with the FDA, which is expected in May 2024
  • 08 Apr 2024 Supernus Pharmaceuticals receives complete response letter from the US FDA for SPN 830 in Parkinson's disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top